Toolkit aims to break the silence around inherited cancer genes

NCT ID NCT04428736

Completed Knowledge-focused Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a 'Disclosure Toolkit'—including a family letter, a chatbot, and a website—helps people with BRCA1 or BRCA2 mutations share their genetic test results with at-risk relatives. Researchers enrolled 52 participants to see if the toolkit improves communication and encourages relatives to get tested. The goal is to find better ways to spread life-saving genetic information within families.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Disclosure Toolkit (family letter, chatbot, website)
What this could lead to: If successful, this toolkit could help more at-risk relatives learn about their genetic risks and get tested, potentially preventing cancer through early detection.
What could go wrong: This is a small, completed study with only 52 participants, so results may not apply to everyone. The toolkit's impact on actual testing rates is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA1 MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRCA1 MUTATION BRCA2 MUTATION

Contacts and locations

Locations

Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.